{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:55:45Z","timestamp":1790823345641,"version":"4.1.0"},"reference-count":157,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82588301"],"award-info":[{"award-number":["82588301"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82120108010"],"award-info":[{"award-number":["82120108010"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82401695"],"award-info":[{"award-number":["82401695"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chongqing Science and Health Joint Fund"},{"name":"Sichuan Science and Technology Program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"DOI":"10.1038\/s41398-026-04188-y","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:23:51Z","timestamp":1783488231000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Could the cognitive benefits of amyloid-beta clearance grow in time for Alzheimer\u2019s disease?"],"prefix":"10.1038","volume":"16","author":[{"given":"Chen-Yang","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan-Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin L.","family":"Masters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6227-6112","authenticated-orcid":false,"given":"Yan-Jiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"4188_CR1","doi-asserted-by":"crossref","unstructured":"2023 Alzheimer\u2019s disease facts and figures. Alzheimers Dement J Alzheimers Assoc 2023;19:1598-695.","DOI":"10.1002\/alz.13016"},{"key":"4188_CR2","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/nep3.23","volume":"1","author":"J Liu","year":"2023","unstructured":"Liu J, van Beusekom H, Bu X-L, Chen G, Henrique Rosado de Castro P, Chen X, et al. Preserving cognitive function in patients with Alzheimer\u2019s disease: The Alzheimer\u2019s disease neuroprotection research initiative (ADNRI). Neuroprotection. 2023;1:84\u201398.","journal-title":"Neuroprotection"},{"key":"4188_CR3","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1016\/j.cell.2023.08.021","volume":"186","author":"M Jucker","year":"2023","unstructured":"Jucker M, Walker LC. Alzheimer\u2019s disease: From immunotherapy to immunoprevention. Cell. 2023;186:4260\u201370.","journal-title":"Cell"},{"key":"4188_CR4","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330:512\u201327.","journal-title":"JAMA"},{"key":"4188_CR5","doi-asserted-by":"publisher","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med 2023;388. https:\/\/doi.org\/10.1056\/NEJMoa2212948.","DOI":"10.1056\/NEJMoa2212948"},{"key":"4188_CR6","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in Early Alzheimer\u2019s disease. N Engl J Med. 2021;384:1691\u2013704.","journal-title":"N Engl J Med"},{"key":"4188_CR7","doi-asserted-by":"publisher","unstructured":"Paczynski M, Hofmann A, Posey Z, Gregersen M, Rudman M, Ellington D, et al. Lecanemab treatment in a specialty memory clinic. JAMA Neurol 2025. https:\/\/doi.org\/10.1001\/jamaneurol.2025.1232.","DOI":"10.1001\/jamaneurol.2025.1232"},{"key":"4188_CR8","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1212\/WNL.0000000000211489","volume":"104","author":"M Irizarry","year":"2025","unstructured":"Irizarry M, van Dyck C, Li D, Dhadda S, Hersch S, Reyderman L, et al. The lecanemab clarity AD open-label extension in early Alzheimer\u2019s disease (P1-3.003). Neurology. 2025;104:4158.","journal-title":"Neurology"},{"key":"4188_CR9","doi-asserted-by":"crossref","unstructured":"Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 2005;64. https:\/\/pubmed.ncbi.nlm.nih.gov\/15642910.","DOI":"10.1212\/01.WNL.0000148604.77591.67"},{"key":"4188_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","volume":"79","author":"S Salloway","year":"2022","unstructured":"Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, et al. Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol. 2022;79:13\u201321.","journal-title":"JAMA Neurol"},{"key":"4188_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/srep39374","volume":"6","author":"M Ultsch","year":"2016","unstructured":"Ultsch M, Li B, Maurer T, Mathieu M, Adolfsson O, Muhs A, et al. Structure of crenezumab complex with A\u03b2 shows loss of \u03b2-Hairpin. Sci Rep. 2016;6:39374.","journal-title":"Sci Rep"},{"key":"4188_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1523\/JNEUROSCI.4337-04.2005","volume":"25","author":"MM Racke","year":"2005","unstructured":"Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci Off J Soc Neurosci. 2005;25:629\u201336.","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"4188_CR13","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jalz.2015.06.1893","volume":"12","author":"ER Siemers","year":"2016","unstructured":"Siemers ER, Sundell KL, Carlson C, Case M, Sethuraman G, Liu-Seifert H, et al. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer\u2019s disease patients. Alzheimers Dement J Alzheimers Assoc. 2016;12:110\u201320.","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"4188_CR14","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1705971","volume":"378","author":"LS Honig","year":"2018","unstructured":"Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, et al. Trial of solanezumab for mild dementia due to Alzheimer\u2019s disease. N Engl J Med. 2018;378:321\u201330.","journal-title":"N Engl J Med"},{"key":"4188_CR15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370:311\u201321.","journal-title":"N Engl J Med"},{"key":"4188_CR16","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13195-018-0424-5","volume":"10","author":"S Salloway","year":"2018","unstructured":"Salloway S, Honigberg LA, Cho W, Ward M, Friesenhahn M, Brunstein F, et al. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer\u2019s disease (BLAZE). Alzheimers Res Ther. 2018;10:96.","journal-title":"Alzheimers Res Ther"},{"key":"4188_CR17","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1212\/WNL.0000000000001877","volume":"85","author":"E Liu","year":"2015","unstructured":"Liu E, Schmidt ME, Margolin R, Sperling R, Koeppe R, Mason NS, et al. Amyloid-\u03b2 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology. 2015;85:692\u2013700.","journal-title":"Neurology"},{"key":"4188_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","volume":"9","author":"S Ostrowitzki","year":"2017","unstructured":"Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease. Alzheimers Res Ther. 2017;9:95.","journal-title":"Alzheimers Res Ther"},{"key":"4188_CR19","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1177\/13872877251361049","volume":"107","author":"LA Miles","year":"2025","unstructured":"Miles LA, Masters CL. The structural foundations of anti-amyloid-\u03b2 immunotherapies: Unravelling antibody-antigen interactions in Alzheimer\u2019s disease treatment. J Alzheimers Dis JAD. 2025;107:393\u2013408.","journal-title":"J Alzheimers Dis JAD"},{"key":"4188_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70224","volume":"21","author":"J Cummings","year":"2025","unstructured":"Cummings J, Cohen S, Murphy J, Brothers HM, Nejati M, Forrestal F, et al. Evaluation of cognitive, functional, and behavioral effects observed in EMERGE, a phase 3 trial of aducanumab in people with early Alzheimer\u2019s disease. Alzheimers Dement J Alzheimers Assoc. 2025;21:e70224.","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"4188_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12382","volume":"9","author":"Y Wang","year":"2023","unstructured":"Wang Y. An insider\u2019s perspective on FDA approval of aducanumab. Alzheimers Dement N Y N. 2023;9:e12382.","journal-title":"Alzheimers Dement N Y N"},{"key":"4188_CR22","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","volume":"76","author":"RB DeMattos","year":"2012","unstructured":"DeMattos RB, Lu J, Tang Y, Racke MM, DeLong CA, Tzaferis JA, et al. A plaque-specific antibody clears existing \u03b2-amyloid plaques in Alzheimer\u2019s disease mice. Neuron. 2012;76:908\u201320.","journal-title":"Neuron"},{"key":"4188_CR23","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1002\/alz.12213","volume":"17","author":"DS Knopman","year":"2021","unstructured":"Knopman DS, Jones DT, Greicius MD. Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimers Dement J Alzheimers Assoc. 2021;17:696\u2013701.","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"4188_CR24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2022;9:197\u2013210.","journal-title":"J Prev Alzheimers Dis"},{"key":"4188_CR25","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","volume":"21","author":"E Karran","year":"2022","unstructured":"Karran E, De Strooper B. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nat Rev Drug Discov. 2022;21:306\u201318.","journal-title":"Nat Rev Drug Discov"},{"key":"4188_CR26","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/S1474-4422(25)00024-9","volume":"24","author":"RJ Bateman","year":"2025","unstructured":"Bateman RJ, Li Y, McDade EM, Llibre-Guerra JJ, Clifford DB, Atri A, et al. Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer\u2019s disease: an open-label extension of the phase 2\/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial. Lancet Neurol. 2025;24:316\u201330.","journal-title":"Lancet Neurol"},{"key":"4188_CR27","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1002\/alz.13755","volume":"20","author":"T Chen","year":"2024","unstructured":"Chen T, O\u2019Gorman J, Castrillo-Viguera C, Rajagovindan R, Curiale GG, Tian Y, et al. Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumab. Alzheimers Dement J Alzheimers Assoc. 2024;20:3406\u201315.","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"4188_CR28","doi-asserted-by":"crossref","unstructured":"van Dyck C The Lecanemab Clarity AD Open-Label Extension in Early Alzheimer\u2019s Disease: Initial Findings From the 48-Month Analysis. Presented at Alzheimer\u2019s Association International Conference (AAIC), Toronto, Canada, 2025. https:\/\/www.prnewswire.com\/news-releases\/bioartic-latest-data-presented-at-aaic-2025-reinforces-lecanemabs-clinical-effect-with-consistent-safety-profile-302518186.html.","DOI":"10.1002\/alz70861_108905"},{"key":"4188_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100446","volume":"13","author":"JA Zimmer","year":"2026","unstructured":"Zimmer JA, Sims JR, Evans CD, Nery ESM, Wang H, Wessels AM, et al. Donanemab in early symptomatic Alzheimer\u2019s disease: results from the TRAILBLAZER-ALZ 2 long-term extension. J Prev Alzheimers Dis. 2026;13:100446.","journal-title":"J Prev Alzheimers Dis"},{"key":"4188_CR30","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41392-022-01273-8","volume":"8","author":"X-Y Sun","year":"2023","unstructured":"Sun X-Y, Yu X-L, Zhu J, Li L-J, Zhang L, Huang Y-R, et al. Fc effector of anti-A\u03b2 antibody induces synapse loss and cognitive deficits in Alzheimer\u2019s disease-like mouse model. Signal Transduct Target Ther. 2023;8:30.","journal-title":"Signal Transduct Target Ther"},{"key":"4188_CR31","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1471-4159.2011.07478.x","volume":"120","author":"ME Larson","year":"2012","unstructured":"Larson ME, Lesn\u00e9 SE. Soluble A\u03b2 oligomer production and toxicity. J Neurochem. 2012;120:125\u201339.","journal-title":"J Neurochem"},{"key":"4188_CR32","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/nm1782","volume":"14","author":"GM Shankar","year":"2008","unstructured":"Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-\u03b2 protein dimers isolated directly from Alzheimer\u2019s brains impair synaptic plasticity and memory. Nat Med. 2008;14:837\u201342.","journal-title":"Nat Med"},{"key":"4188_CR33","doi-asserted-by":"publisher","first-page":"32046","DOI":"10.1074\/jbc.M201750200","volume":"277","author":"KN Dahlgren","year":"2002","unstructured":"Dahlgren KN, Manelli AM, Stine WB, Baker LK, Krafft GA, LaDu MJ. Oligomeric and fibrillar species of Amyloid-\u03b2 peptides differentially affect neuronal viability. J Biol Chem. 2002;277:32046\u201353.","journal-title":"J Biol Chem"},{"key":"4188_CR34","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrneurol.2012.118","volume":"8","author":"Y-H Liu","year":"2012","unstructured":"Liu Y-H, Giunta B, Zhou H-D, Tan J, Wang Y-J. Immunotherapy for Alzheimer disease\u2014the challenge of adverse effects. Nat Rev Neurol. 2012;8:465\u20139.","journal-title":"Nat Rev Neurol"},{"key":"4188_CR35","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nrneurol.2017.111","volume":"13","author":"J Wang","year":"2017","unstructured":"Wang J, Gu BJ, Masters CL, Wang Y-J. A systemic view of Alzheimer disease - insights from amyloid-\u03b2 metabolism beyond the brain. Nat Rev Neurol. 2017;13:612\u201323.","journal-title":"Nat Rev Neurol"},{"key":"4188_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-015-0379-4","volume":"12","author":"Y-H Liu","year":"2015","unstructured":"Liu Y-H, Bu X-L, Liang C-R, Wang Y-R, Zhang T, Jiao S-S, et al. An N-terminal antibody promotes the transformation of amyloid fibrils into oligomers and enhances the neurotoxicity of amyloid-beta: the dust-raising effect. J Neuroinflammation. 2015;12:153.","journal-title":"J Neuroinflammation"},{"key":"4188_CR37","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3233\/JAD-140741","volume":"43","author":"S Tucker","year":"2015","unstructured":"Tucker S, M\u00f6ller C, Tegerstedt K, Lord A, Laudon H, Sj\u00f6dahl J, et al. The murine version of BAN2401 (mAb158) selectively reduces amyloid-\u03b2 protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis JAD. 2015;43:575\u201388.","journal-title":"J Alzheimers Dis JAD"},{"key":"4188_CR38","doi-asserted-by":"crossref","unstructured":"Hendrix S, Whetten J, Hendrix K Benefit Contin-ues to Accumulate When Treatment is Continued Beyond Plaque Clearance - Estimating Accuinulated or Maintained Treatment Bene-fitin the CLARITY-AD and TR\/AILBLAZER-ALZ 2 Trials. San Diego, CA, United States, 2025.","DOI":"10.1212\/WNL.0000000000215643"},{"key":"4188_CR39","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl). 1991;82:239\u201359.","journal-title":"Acta Neuropathol (Berl)"},{"key":"4188_CR40","doi-asserted-by":"publisher","unstructured":"Boldrini M, Fulmore CA, Tartt AN, Simeon LR, Pavlova I, Poposka V, et al. Human hippocampal neurogenesis persists throughout aging. Cell Stem Cell 2018;22. https:\/\/doi.org\/10.1016\/j.stem.2018.03.015.","DOI":"10.1016\/j.stem.2018.03.015"},{"key":"4188_CR41","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1126\/science.adj9255","volume":"382","author":"TE Golde","year":"2023","unstructured":"Golde TE, Levey AI. Immunotherapies for Alzheimer\u2019s disease. Science. 2023;382:1242\u20134.","journal-title":"Science"},{"key":"4188_CR42","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","volume":"9","author":"CR Jack","year":"2010","unstructured":"Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade. Lancet Neurol. 2010;9:119\u201328.","journal-title":"Lancet Neurol"},{"key":"4188_CR43","volume":"12","author":"S-G Yang","year":"2025","unstructured":"Yang S-G, Li C-P, Wang X-W, Huang T, Qian C, Li Q, et al. Roles of Kdm6a and Kdm6b in Regulation of Mammalian Neural Regeneration. Adv Sci Weinh Baden-Wurtt Ger. 2025;12:e2405537.","journal-title":"Adv Sci Weinh Baden-Wurtt Ger"},{"key":"4188_CR44","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/s41591-024-02931-w","volume":"30","author":"J Fortea","year":"2024","unstructured":"Fortea J, Pegueroles J, Alcolea D, Belbin O, Dols-Icardo O, Vaqu\u00e9-Alc\u00e1zar L, et al. APOE4 homozygozity represents a distinct genetic form of Alzheimer\u2019s disease. Nat Med. 2024;30:1284\u201391.","journal-title":"Nat Med"},{"key":"4188_CR45","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41588-022-01024-z","volume":"54","author":"C Bellenguez","year":"2022","unstructured":"Bellenguez C, K\u00fc\u00e7\u00fckali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N, et al. New insights into the genetic etiology of Alzheimer\u2019s disease and related dementias. Nat Genet. 2022;54:412\u201336.","journal-title":"Nat Genet"},{"key":"4188_CR46","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13195-020-00740-0","volume":"13","author":"A Gharbi-Meliani","year":"2021","unstructured":"Gharbi-Meliani A, Dugravot A, Sabia S, Regy M, Fayosse A, Schnitzler A, et al. The association of APOE \u03b54 with cognitive function over the adult life course and incidence of dementia: 20\u2009years follow-up of the Whitehall II study. Alzheimers Res Ther. 2021;13:5.","journal-title":"Alzheimers Res Ther"},{"key":"4188_CR47","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41586-022-05439-w","volume":"611","author":"JW Blanchard","year":"2022","unstructured":"Blanchard JW, Akay LA, Davila-Velderrain J, von Maydell D, Mathys H, Davidson SM, et al. APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes. Nature. 2022;611:769\u201379.","journal-title":"Nature"},{"key":"4188_CR48","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-018-0297-y","volume":"25","author":"DA Nation","year":"2019","unstructured":"Nation DA, Sweeney MD, Montagne A, Sagare AP, D\u2019Orazio LM, Pachicano M, et al. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med. 2019;25:270\u20136.","journal-title":"Nat Med"},{"key":"4188_CR49","doi-asserted-by":"publisher","first-page":"39941","DOI":"10.18632\/oncotarget.17990","volume":"8","author":"JE Pankiewicz","year":"2017","unstructured":"Pankiewicz JE, Sadowski MJ. APOE genotype and Alzheimer\u2019s immunotherapy. Oncotarget. 2017;8:39941\u20132.","journal-title":"Oncotarget"},{"key":"4188_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70586","volume":"21","author":"JSM Tsui","year":"2025","unstructured":"Tsui JSM, Au DM, Uhm H, Wong W-W, Lo RMN, Jiang Y, et al. The TREM2 H157Y variant is associated with more severe neurodegeneration in Alzheimer\u2019s disease and altered immune-related processes. Alzheimers Dement J Alzheimers Assoc. 2025;21:e70586.","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"4188_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09118-9","volume":"10","author":"L Zhong","year":"2019","unstructured":"Zhong L, Xu Y, Zhuo R, Wang T, Wang K, Huang R, et al. Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer\u2019s disease model. Nat Commun. 2019;10:1365.","journal-title":"Nat Commun"},{"key":"4188_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34679-7","volume":"13","author":"G Lord\u00e9n","year":"2022","unstructured":"Lord\u00e9n G, Wozniak JM, Dor\u00e9 K, Dozier LE, Cates-Gatto C, Patrick GN, et al. Enhanced activity of Alzheimer disease-associated variant of protein kinase C\u03b1 drives cognitive decline in a mouse model. Nat Commun. 2022;13:7200.","journal-title":"Nat Commun"},{"key":"4188_CR53","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70660","volume":"21","author":"MY Chun","year":"2025","unstructured":"Chun MY, Jung S-H, Choe J, Lee S-Y, Kim H-R, Son HJ, et al. Polygenic risk score of Alzheimer\u2019s disease is associated with cognitive trajectories and phenotypes of cerebral organoids. Alzheimers Dement J Alzheimers Assoc. 2025;21:e70660.","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"4188_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.104978","volume":"101","author":"Y Freudenberg-Hua","year":"2024","unstructured":"Freudenberg-Hua Y, Li W, Lee UJ, Ma Y, Koppel J, Goate A. Association between pre-dementia psychiatric diagnoses and all-cause dementia is independent from polygenic dementia risks in the UK Biobank. EBioMedicine. 2024;101:104978.","journal-title":"EBioMedicine"},{"key":"4188_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2025.102699","volume":"106","author":"F Bellelli","year":"2025","unstructured":"Bellelli F, Angioni D, Arosio B, Vellas B, De Souto Barreto P. Hallmarks of aging and Alzheimer\u2019s Disease pathogenesis: Paving the route for new therapeutic targets. Ageing Res Rev. 2025;106:102699.","journal-title":"Ageing Res Rev"},{"key":"4188_CR56","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207920","volume":"102","author":"OL Lopez","year":"2024","unstructured":"Lopez OL, Villemagne VL, Chang Y-F, Cohen AD, Klunk WE, Mathis CA, et al. Association between \u03b2-Amyloid accumulation and incident dementia in individuals 80 years or older without dementia. Neurology. 2024;102:e207920.","journal-title":"Neurology"},{"key":"4188_CR57","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s11357-023-00982-4","volume":"46","author":"SP da Silva","year":"2024","unstructured":"da Silva SP, de Castro CCM, Rabelo LN, Engelberth RC, Fern\u00e1ndez-Calvo B, Fiuza FP. Neuropathological and sociodemographic factors associated with the cortical amyloid load in aging and Alzheimer\u2019s disease. GeroScience. 2024;46:621\u201343.","journal-title":"GeroScience"},{"key":"4188_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102540","volume":"101","author":"A Ajoolabady","year":"2024","unstructured":"Ajoolabady A, Pratico D, Tang D, Zhou S, Franceschi C, Ren J. Immunosenescence and inflammaging: Mechanisms and role in diseases. Ageing Res Rev. 2024;101:102540.","journal-title":"Ageing Res Rev"},{"key":"4188_CR59","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41593-022-01238-8","volume":"26","author":"G Bieri","year":"2023","unstructured":"Bieri G, Schroer AB, Villeda SA. Blood-to-brain communication in aging and rejuvenation. Nat Neurosci. 2023;26:379\u201393.","journal-title":"Nat Neurosci"},{"key":"4188_CR60","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41586-022-04722-0","volume":"605","author":"T Iram","year":"2022","unstructured":"Iram T, Kern F, Kaur A, Myneni S, Morningstar AR, Shin H, et al. Young CSF restores oligodendrogenesis and memory in aged mice via Fgf17. Nature. 2022;605:509\u201315.","journal-title":"Nature"},{"key":"4188_CR61","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41593-020-00745-w","volume":"24","author":"W-N Jin","year":"2021","unstructured":"Jin W-N, Shi K, He W, Sun J-H, Van Kaer L, Shi F-D, et al. Neuroblast senescence in the aged brain augments natural killer cell cytotoxicity leading to impaired neurogenesis and cognition. Nat Neurosci. 2021;24:61\u201373.","journal-title":"Nat Neurosci"},{"key":"4188_CR62","first-page":"427","volume":"awaf","author":"L-L Li","year":"2025","unstructured":"Li L-L, Wang R-Z, Wang Z, Hu H, Xu W, Zhu L, et al. Safety and short-term outcomes of lecanemab for Alzheimer\u2019s disease in China: a multicentre study. Brain J Neurol. 2025;awaf:427.","journal-title":"Brain J Neurol"},{"key":"4188_CR63","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13024-024-00758-0","volume":"19","author":"X Taylor","year":"2024","unstructured":"Taylor X, Noristani HN, Fitzgerald GJ, Oluoch H, Babb N, McGathey T, et al. Amyloid-\u03b2 (A\u03b2) immunotherapy induced microhemorrhages are linked to vascular inflammation and cerebrovascular damage in a mouse model of Alzheimer\u2019s disease. Mol Neurodegener. 2024;19:77.","journal-title":"Mol Neurodegener"},{"key":"4188_CR64","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.tins.2021.06.007","volume":"44","author":"A Guerrero","year":"2021","unstructured":"Guerrero A, De Strooper B, Arancibia-C\u00e1rcamo IL. Cellular senescence at the crossroads of inflammation and Alzheimer\u2019s disease. Trends Neurosci. 2021;44:714\u201327.","journal-title":"Trends Neurosci"},{"key":"4188_CR65","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1161\/STR.0b013e3182299496","volume":"42","author":"PB Gorelick","year":"2011","unstructured":"Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association\/american stroke association. Stroke. 2011;42:2672\u2013713.","journal-title":"Stroke"},{"key":"4188_CR66","doi-asserted-by":"publisher","first-page":"9896","DOI":"10.1523\/JNEUROSCI.1762-16.2016","volume":"36","author":"EM Weekman","year":"2016","unstructured":"Weekman EM, Sudduth TL, Caverly CN, Kopper TJ, Phillips OW, Powell DK, et al. Reduced efficacy of Anti-A\u03b2 immunotherapy in a mouse model of amyloid deposition and vascular cognitive impairment comorbidity. J Neurosci Off J Soc Neurosci. 2016;36:9896\u2013907.","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"4188_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60748-8","volume":"16","author":"X-L Bu","year":"2025","unstructured":"Bu X-L, Zhu W, Wang Q-H, Liu Z-T, Bao Y-Y, Bai Y-D, et al. Association between self-reported multimorbidity and longitudinal brain A\u03b2 deposition in Alzheimer\u2019s disease. Nat Commun. 2025;16:5905.","journal-title":"Nat Commun"},{"key":"4188_CR68","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13195-025-01761-3","volume":"17","author":"J Wu","year":"2025","unstructured":"Wu J, Yin X, Ji W, Liu Y, Tang J, Zhang H, et al. Hypertension and diabetes on cognitive impairment: a case-control study in China. Alzheimers Res Ther. 2025;17:120.","journal-title":"Alzheimers Res Ther"},{"key":"4188_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2019.100944","volume":"55","author":"M Xue","year":"2019","unstructured":"Xue M, Xu W, Ou Y-N, Cao X-P, Tan M-S, Tan L, et al. Diabetes mellitus and risks of cognitive impairment and dementia: A systematic review and meta-analysis of 144 prospective studies. Ageing Res Rev. 2019;55:100944.","journal-title":"Ageing Res Rev"},{"key":"4188_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-5-51","volume":"5","author":"B Giunta","year":"2008","unstructured":"Giunta B, Fernandez F, Nikolic WV, Obregon D, Rrapo E, Town T, et al. Inflammaging as a prodrome to Alzheimer\u2019s disease. J Neuroinflammation. 2008;5:51.","journal-title":"J Neuroinflammation"},{"key":"4188_CR71","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13024-019-0320-x","volume":"14","author":"D Twohig","year":"2019","unstructured":"Twohig D, Nielsen HM. \u03b1-synuclein in the pathophysiology of Alzheimer\u2019s disease. Mol Neurodegener. 2019;14:23.","journal-title":"Mol Neurodegener"},{"key":"4188_CR72","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1001\/jamaneurol.2025.0065","volume":"82","author":"JA Zimmer","year":"2025","unstructured":"Zimmer JA, Ardayfio P, Wang H, Khanna R, Evans CD, Lu M, et al. Amyloid-related imaging abnormalities with donanemab in early symptomatic Alzheimer disease: Secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials. JAMA Neurol. 2025;82:461\u20139.","journal-title":"JAMA Neurol"},{"key":"4188_CR73","doi-asserted-by":"publisher","DOI":"10.1126\/science.ads3204","volume":"389","author":"ME Pizzo","year":"2025","unstructured":"Pizzo ME, Plowey ED, Khoury N, Kwan W, Abettan J, DeVos SL, et al. Transferrin receptor-targeted anti-amyloid antibody enhances brain delivery and mitigates ARIA. Science. 2025;389:eads3204.","journal-title":"Science"},{"key":"4188_CR74","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1093\/brain\/awad159","volume":"146","author":"KP Kepp","year":"2023","unstructured":"Kepp KP, Robakis NK, H\u00f8ilund-Carlsen PF, Sensi SL, Vissel B. The amyloid cascade hypothesis: an updated critical review. Brain J Neurol. 2023;146:3969\u201390.","journal-title":"Brain J Neurol"},{"key":"4188_CR75","doi-asserted-by":"publisher","unstructured":"Mix MR, Kreitlow BL, Berton RR, Xu J, Fain CE, van de Wall S, et al. Physiological microbial exposure normalizes memory T cell surveillance of the brain and modifies host seizure outcomes. Nat Immunol 2025. https:\/\/doi.org\/10.1038\/s41590-025-02174-y.","DOI":"10.1038\/s41590-025-02174-y"},{"key":"4188_CR76","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2427257122","volume":"122","author":"L Tian","year":"2025","unstructured":"Tian L, Long G, Zhu S, Wang Y, Xu P, Liu L, et al. Nanoimmunomodulation of the A\u03b2-STING feedback machinery in microglia for Alzheimer\u2019s disease treatment. Proc Natl Acad Sci USA. 2025;122:e2427257122.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4188_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchemneu.2021.101945","volume":"114","author":"L Zhu","year":"2021","unstructured":"Zhu L, Lu F, Jia X, Yan Q, Zhang X, Mu P. Amyloid-\u03b2 (25-35) regulates neuronal damage and memory loss via SIRT1\/Nrf2 in the cortex of mice. J Chem Neuroanat. 2021;114:101945.","journal-title":"J Chem Neuroanat"},{"key":"4188_CR78","volume":"141","author":"T Yu","year":"2025","unstructured":"Yu T, Wei Z, Wang J, Song C, Huang W, Zhang P, et al. Ginkgo biloba Extract GBE50 ameliorates cerebrovascular dysfunction and cognitive impairment in a mouse model of Alzheimer\u2019s disease. Phytomedicine Int J Phytother Phytopharm. 2025;141:156646.","journal-title":"Phytomedicine Int J Phytother Phytopharm"},{"key":"4188_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.951415","volume":"9","author":"X Xie","year":"2022","unstructured":"Xie X, Wan J, Zheng X, Pan W, Yuan J, Hu B, et al. Synergistic effects of epigallocatechin gallate and l-theanine in nerve repair and regeneration by anti-amyloid damage, promoting metabolism, and nourishing nerve cells. Front Nutr. 2022;9:951415.","journal-title":"Front Nutr"},{"key":"4188_CR80","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.tins.2017.01.002","volume":"40","author":"JS Kerr","year":"2017","unstructured":"Kerr JS, Adriaanse BA, Greig NH, Mattson MP, Cader MZ, Bohr VA, et al. Mitophagy and Alzheimer\u2019s disease: cellular and molecular mechanisms. Trends Neurosci. 2017;40:151\u201366.","journal-title":"Trends Neurosci"},{"key":"4188_CR81","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/cns.13086","volume":"25","author":"X Jin","year":"2019","unstructured":"Jin X, Liu M-Y, Zhang D-F, Zhong X, Du K, Qian P, et al. Baicalin mitigates cognitive impairment and protects neurons from microglia-mediated neuroinflammation via suppressing NLRP3 inflammasomes and TLR4\/NF-\u03baB signaling pathway. CNS Neurosci Ther. 2019;25:575\u201390.","journal-title":"CNS Neurosci Ther"},{"key":"4188_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-021-02158-3","volume":"18","author":"J Rostami","year":"2021","unstructured":"Rostami J, Mothes T, Kolahdouzan M, Eriksson O, Moslem M, Bergstr\u00f6m J, et al. Crosstalk between astrocytes and microglia results in increased degradation of \u03b1-synuclein and amyloid-\u03b2 aggregates. J Neuroinflammation. 2021;18:124.","journal-title":"J Neuroinflammation"},{"key":"4188_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101622","volume":"78","author":"MS Uddin","year":"2022","unstructured":"Uddin MS, Lim LW. Glial cells in Alzheimer\u2019s disease: From neuropathological changes to therapeutic implications. Ageing Res Rev. 2022;78:101622.","journal-title":"Ageing Res Rev"},{"key":"4188_CR84","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1038\/s41591-025-03574-1","volume":"31","author":"L van Olst","year":"2025","unstructured":"van Olst L, Simonton B, Edwards AJ, Forsyth AV, Boles J, Jamshidi P, et al. Microglial mechanisms drive amyloid-\u03b2 clearance in immunized patients with Alzheimer\u2019s disease. Nat Med. 2025;31:1604\u201316.","journal-title":"Nat Med"},{"key":"4188_CR85","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.nbd.2014.08.011","volume":"71","author":"A Pisanu","year":"2014","unstructured":"Pisanu A, Lecca D, Mulas G, Wardas J, Simbula G, Spiga S, et al. Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-\u03b3 agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson\u2019s disease. Neurobiol Dis. 2014;71:280\u201391.","journal-title":"Neurobiol Dis"},{"key":"4188_CR86","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40035-020-00221-2","volume":"9","author":"HS Kwon","year":"2020","unstructured":"Kwon HS, Koh S-H. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener. 2020;9:42.","journal-title":"Transl Neurodegener"},{"key":"4188_CR87","volume":"128","author":"W Wang","year":"2024","unstructured":"Wang W, Wang Y, Wang F, Xie G, Liu S, Li Z, et al. Gastrodin regulates the TLR4\/TRAF6\/NF-\u03baB pathway to reduce neuroinflammation and microglial activation in an AD model. Phytomedicine Int J Phytother Phytopharm. 2024;128:155518.","journal-title":"Phytomedicine Int J Phytother Phytopharm"},{"key":"4188_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115219","volume":"207","author":"T Lei","year":"2024","unstructured":"Lei T, Yang Z, Li H, Qin M, Gao H. Interactions between nanoparticles and pathological changes of vascular in Alzheimer\u2019s disease. Adv Drug Deliv Rev. 2024;207:115219.","journal-title":"Adv Drug Deliv Rev"},{"key":"4188_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110131","volume":"127","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Liu H, Zhao Z, Zang C, Ju C, Li F, et al. GJ-4 alleviates A\u03b225-35-induced memory dysfunction in mice through protecting the neurovascular unit. Biomed Pharmacother Biomedecine Pharmacother. 2020;127:110131.","journal-title":"Biomed Pharmacother Biomedecine Pharmacother"},{"key":"4188_CR90","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1161\/CIRCRESAHA.110.233080","volume":"107","author":"SA Austin","year":"2010","unstructured":"Austin SA, Santhanam AV, Katusic ZS. Endothelial nitric oxide modulates expression and processing of amyloid precursor protein. Circ Res. 2010;107:1498\u2013502.","journal-title":"Circ Res"},{"key":"4188_CR91","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13195-024-01423-w","volume":"16","author":"S Chen","year":"2024","unstructured":"Chen S, Guo D, Zhu Y, Xiao S, Xie J, Zhang Z, et al. Amyloid \u03b2 oligomer induces cerebral vasculopathy via pericyte-mediated endothelial dysfunction. Alzheimers Res Ther. 2024;16:56.","journal-title":"Alzheimers Res Ther"},{"key":"4188_CR92","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.4103\/1673-5374.335829","volume":"17","author":"Y-L Zhang","year":"2022","unstructured":"Zhang Y-L, Wang J, Zhang Z-N, Su Q, Guo J-H. The relationship between amyloid-beta and brain capillary endothelial cells in Alzheimer\u2019s disease. Neural Regen Res. 2022;17:2355\u201363.","journal-title":"Neural Regen Res"},{"key":"4188_CR93","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40478-015-0193-3","volume":"3","author":"JM Decker","year":"2015","unstructured":"Decker JM, Kr\u00fcger L, Sydow A, Zhao S, Frotscher M, Mandelkow E, et al. Pro-aggregant Tau impairs mossy fiber plasticity due to structural changes and Ca(++) dysregulation. Acta Neuropathol Commun. 2015;3:23.","journal-title":"Acta Neuropathol Commun"},{"key":"4188_CR94","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1021\/acschemneuro.0c00811","volume":"12","author":"G Fani","year":"2021","unstructured":"Fani G, Mannini B, Vecchi G, Cascella R, Cecchi C, Dobson CM, et al. A\u03b2 oligomers dysregulate calcium homeostasis by mechanosensitive activation of AMPA and NMDA receptors. ACS Chem Neurosci. 2021;12:766\u201381.","journal-title":"ACS Chem Neurosci"},{"key":"4188_CR95","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13024-017-0169-9","volume":"12","author":"M Arbel-Ornath","year":"2017","unstructured":"Arbel-Ornath M, Hudry E, Boivin JR, Hashimoto T, Takeda S, Kuchibhotla KV, et al. Soluble oligomeric amyloid-\u03b2 induces calcium dyshomeostasis that precedes synapse loss in the living mouse brain. Mol Neurodegener. 2017;12:27.","journal-title":"Mol Neurodegener"},{"key":"4188_CR96","doi-asserted-by":"publisher","first-page":"5568","DOI":"10.1007\/s12035-019-1467-8","volume":"56","author":"B Bie","year":"2019","unstructured":"Bie B, Wu J, Foss JF, Naguib M. Activation of mGluR1 mediates C1q-Dependent microglial phagocytosis of glutamatergic synapses in Alzheimer\u2019s rodent models. Mol Neurobiol. 2019;56:5568\u201385.","journal-title":"Mol Neurobiol"},{"key":"4188_CR97","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41591-025-03565-2","volume":"31","author":"HS-H Oh","year":"2025","unstructured":"Oh HS-H, Urey DY, Karlsson L, Zhu Z, Shen Y, Farinas A, et al. A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer\u2019s disease. Nat Med. 2025;31:1592\u2013603.","journal-title":"Nat Med"},{"key":"4188_CR98","doi-asserted-by":"publisher","first-page":"e99184","DOI":"10.1371\/journal.pone.0099184","volume":"9","author":"GM Gomes","year":"2014","unstructured":"Gomes GM, Dalmolin GD, B\u00e4r J, Karpova A, Mello CF, Kreutz MR, et al. Inhibition of the polyamine system counteracts \u03b2-amyloid peptide-induced memory impairment in mice: involvement of extrasynaptic NMDA receptors. PloS One. 2014;9:e99184.","journal-title":"PloS One"},{"key":"4188_CR99","doi-asserted-by":"publisher","first-page":"5940","DOI":"10.1002\/alz.14044","volume":"20","author":"LH Gallo","year":"2024","unstructured":"Gallo LH, Akanda N, Autar K, Patel A, Cox I, Powell HA, et al. A functional aged human iPSC-cortical neuron model recapitulates Alzheimer\u2019s disease, senescence, and the response to therapeutics. Alzheimers Dement J Alzheimers Assoc. 2024;20:5940\u201360.","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"4188_CR100","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1126\/science.aad8373","volume":"352","author":"S Hong","year":"2016","unstructured":"Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352:712\u20136.","journal-title":"Science"},{"key":"4188_CR101","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s12276-023-01148-0","volume":"56","author":"J Kim","year":"2024","unstructured":"Kim J, Yoo ID, Lim J, Moon J-S. Pathological phenotypes of astrocytes in Alzheimer\u2019s disease. Exp Mol Med. 2024;56:95\u201399.","journal-title":"Exp Mol Med"},{"key":"4188_CR102","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40035-023-00344-2","volume":"12","author":"S Somin","year":"2023","unstructured":"Somin S, Kulasiri D, Samarasinghe S. Alleviating the unwanted effects of oxidative stress on A\u03b2 clearance: a review of related concepts and strategies for the development of computational modelling. Transl Neurodegener. 2023;12:11.","journal-title":"Transl Neurodegener"},{"key":"4188_CR103","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/S0891-5849(02)00794-3","volume":"32","author":"DA Butterfield","year":"2002","unstructured":"Butterfield DA, Lauderback CM. Lipid peroxidation and protein oxidation in Alzheimer\u2019s disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic Biol Med. 2002;32:1050\u201360.","journal-title":"Free Radic Biol Med"},{"key":"4188_CR104","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1046\/j.1471-4159.1997.68010255.x","volume":"68","author":"RJ Mark","year":"1997","unstructured":"Mark RJ, Lovell MA, Markesbery WR, Uchida K, Mattson MP. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. J Neurochem. 1997;68:255\u201364.","journal-title":"J Neurochem"},{"key":"4188_CR105","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1152\/physrev.00030.2022","volume":"104","author":"M Perluigi","year":"2024","unstructured":"Perluigi M, Di Domenico F, Butterfield DA. Oxidative damage in neurodegeneration: roles in the pathogenesis and progression of Alzheimer disease. Physiol Rev. 2024;104:103\u201397.","journal-title":"Physiol Rev"},{"key":"4188_CR106","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.freeradbiomed.2010.11.026","volume":"51","author":"M Dumont","year":"2011","unstructured":"Dumont M, Beal MF. Neuroprotective strategies involving ROS in Alzheimer disease. Free Radic Biol Med. 2011;51:1014\u201326.","journal-title":"Free Radic Biol Med"},{"key":"4188_CR107","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/7419389","volume":"2016","author":"W-Q Li","year":"2016","unstructured":"Li W-Q, Wang Z-J, Liu S, Hu Y, Yin M, Lu Y. N-Stearoyl-L-Tyrosine inhibits the senescence of neural stem\/progenitor cells induced by A\u03b2 1-42 via the CB2 receptor. Stem Cells Int. 2016;2016:7419389.","journal-title":"Stem Cells Int"},{"key":"4188_CR108","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.4103\/NRR.NRR-D-23-01628","volume":"20","author":"K Goncalves","year":"2025","unstructured":"Goncalves K, Przyborski S. Modulation of the Nogo signaling pathway to overcome amyloid-\u03b2-mediated neurite inhibition in human pluripotent stem cell-derived neurites. Neural Regen Res. 2025;20:2645\u201354.","journal-title":"Neural Regen Res"},{"key":"4188_CR109","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jphs.2016.08.009","volume":"132","author":"S Liu","year":"2016","unstructured":"Liu S, Tang S-Q, Cui H-J, Yin S, Yin M, Zhao H, et al. Dipotassium N-stearoyltyrosinate ameliorated pathological injuries in triple-transgenic mouse model of Alzheimer\u2019s disease. J Pharmacol Sci. 2016;132:92\u201399.","journal-title":"J Pharmacol Sci"},{"key":"4188_CR110","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/j.1474-9726.2012.00797.x","volume":"11","author":"R Blaise","year":"2012","unstructured":"Blaise R, Mateo V, Rouxel C, Zaccarini F, Glorian M, B\u00e9r\u00e9ziat G, et al. Wild-type amyloid beta 1-40 peptide induces vascular smooth muscle cell death independently from matrix metalloprotease activity. Aging Cell. 2012;11:384\u201393.","journal-title":"Aging Cell"},{"key":"4188_CR111","volume":"11","author":"Q Yang","year":"2024","unstructured":"Yang Q, Yan C, Sun Y, Xie Z, Yang L, Jiang M, et al. Extracellular matrix remodeling alleviates memory deficits in Alzheimer\u2019s disease by enhancing the astrocytic autophagy-lysosome pathway. Adv Sci Weinh Baden-Wurtt Ger. 2024;11:e2400480.","journal-title":"Adv Sci Weinh Baden-Wurtt Ger"},{"key":"4188_CR112","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1161\/CIRCRESAHA.123.324055","volume":"134","author":"Y Fu","year":"2024","unstructured":"Fu Y, Zhou Y, Wang K, Li Z, Kong W. Extracellular matrix interactome in modulating vascular homeostasis and remodeling. Circ Res. 2024;134:931\u201349.","journal-title":"Circ Res"},{"key":"4188_CR113","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.4103\/NRR.NRR-D-24-00146","volume":"20","author":"DS MacDonald","year":"2025","unstructured":"MacDonald DS, Penney J. Microglial dysfunction and genetic risk for neurodegenerative disease. Neural Regen Res. 2025;20:1401\u20132.","journal-title":"Neural Regen Res"},{"key":"4188_CR114","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/alz.12683","volume":"19","author":"T Ashleigh","year":"2023","unstructured":"Ashleigh T, Swerdlow RH, Beal MF. The role of mitochondrial dysfunction in Alzheimer\u2019s disease pathogenesis. Alzheimers Dement J Alzheimers Assoc. 2023;19:333\u201342.","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"4188_CR115","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1523\/JNEUROSCI.17-03-01046.1997","volume":"17","author":"RJ Mark","year":"1997","unstructured":"Mark RJ, Pang Z, Geddes JW, Uchida K, Mattson MP. Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J Neurosci Off J Soc Neurosci. 1997;17:1046\u201354.","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"4188_CR116","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/s42255-022-00643-4","volume":"4","author":"L Leng","year":"2022","unstructured":"Leng L, Yuan Z, Pan R, Su X, Wang H, Xue J, et al. Microglial hexokinase 2 deficiency increases ATP generation through lipid metabolism leading to \u03b2-amyloid clearance. Nat Metab. 2022;4:1287\u2013305.","journal-title":"Nat Metab"},{"key":"4188_CR117","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1126\/science.aay0198","volume":"365","author":"B Zott","year":"2019","unstructured":"Zott B, Simon MM, Hong W, Unger F, Chen-Engerer H-J, Frosch MP, et al. A vicious cycle of \u03b2 amyloid-dependent neuronal hyperactivation. Science. 2019;365:559\u201365.","journal-title":"Science"},{"key":"4188_CR118","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14380","volume":"21","author":"L Cui","year":"2025","unstructured":"Cui L, Zhang Z, Tu Y-Y, Wang M, Guan Y-H, Li Y-H, et al. Association of precuneus A\u03b2 burden with default mode network function. Alzheimers Dement J Alzheimers Assoc. 2025;21:e14380.","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"4188_CR119","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1038\/s41380-024-02779-z","volume":"30","author":"F Mandino","year":"2025","unstructured":"Mandino F, Shen X, Desrosiers-Gr\u00e9goire G, O\u2019Connor D, Mukherjee B, Owens A, et al. Aging-dependent loss of functional connectivity in a mouse model of Alzheimer\u2019s disease and reversal by mGluR5 modulator. Mol Psychiatry. 2025;30:1730\u201345.","journal-title":"Mol Psychiatry"},{"key":"4188_CR120","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20231363","volume":"221","author":"MP Cadiz","year":"2024","unstructured":"Cadiz MP, Gibson KA, Todd KT, Nascari DG, Massa N, Lilley MT, et al. Aducanumab anti-amyloid immunotherapy induces sustained microglial and immune alterations. J Exp Med. 2024;221:e20231363.","journal-title":"J Exp Med"},{"key":"4188_CR121","doi-asserted-by":"publisher","first-page":"e1347","DOI":"10.1212\/WNL.0000000000011524","volume":"96","author":"WJ Jagust","year":"2021","unstructured":"Jagust WJ, Landau SM. Alzheimer\u2019s disease neuroimaging initiative. temporal dynamics of \u03b2-Amyloid accumulation in aging and Alzheimer disease. Neurology. 2021;96:e1347\u2013e1357.","journal-title":"Neurology"},{"key":"4188_CR122","first-page":"P1377","volume":"64","author":"F Yang","year":"2023","unstructured":"Yang F, Maher M, Dutta J. An SCCA-clustering framework for Alzheimer\u2019s disease subtyping using tau PET and genomics. J Nucl Med. 2023;64:P1377.","journal-title":"J Nucl Med"},{"key":"4188_CR123","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2021.1858","volume":"78","author":"R Ossenkoppele","year":"2021","unstructured":"Ossenkoppele R, Smith R, Mattsson-Carlgren N, Groot C, Leuzy A, Strandberg O, et al. Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: A Head-to-Head comparison against amyloid positron emission tomography and magnetic resonance imaging. JAMA Neurol. 2021;78:961\u201371.","journal-title":"JAMA Neurol"},{"key":"4188_CR124","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60395-z","volume":"16","author":"NJ Schork","year":"2025","unstructured":"Schork NJ, Goetz LH. From precision interventions to precision health. Nat Commun. 2025;16:5024.","journal-title":"Nat Commun"},{"key":"4188_CR125","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13024-021-00452-5","volume":"16","author":"M Seto","year":"2021","unstructured":"Seto M, Weiner RL, Dumitrescu L, Hohman TJ. Protective genes and pathways in Alzheimer\u2019s disease: moving towards precision interventions. Mol Neurodegener. 2021;16:29.","journal-title":"Mol Neurodegener"},{"key":"4188_CR126","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1474-4422(17)30159-X","volume":"16","author":"GB Frisoni","year":"2017","unstructured":"Frisoni GB, Boccardi M, Barkhof F, Blennow K, Cappa S, Chiotis K, et al. Strategic roadmap for an early diagnosis of Alzheimer\u2019s disease based on biomarkers. Lancet Neurol. 2017;16:661\u201376.","journal-title":"Lancet Neurol"},{"key":"4188_CR127","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jalz.2013.10.007","volume":"10","author":"HM Snyder","year":"2014","unstructured":"Snyder HM, Carrillo MC, Grodstein F, Henriksen K, Jeromin A, Lovestone S, et al. Developing novel blood-based biomarkers for Alzheimer\u2019s disease. Alzheimers Dement J Alzheimers Assoc. 2014;10:109\u201314.","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"4188_CR128","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/JCMA.0000000000001252","volume":"88","author":"C-K Wu","year":"2025","unstructured":"Wu C-K, Fuh J-L. A 2025 update on treatment strategies for the Alzheimer\u2019s disease spectrum. J Chin Med Assoc. 2025;88:495\u2013502.","journal-title":"J Chin Med Assoc"},{"key":"4188_CR129","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40120-022-00416-x","volume":"12","author":"X Li","year":"2023","unstructured":"Li X, Ji M, Zhang H, Liu Z, Chai Y, Cheng Q, et al. Non-drug Therapies for Alzheimer\u2019s disease: a review. Neurol Ther. 2023;12:39\u201372.","journal-title":"Neurol Ther"},{"key":"4188_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.102127","volume":"92","author":"X Zhang","year":"2023","unstructured":"Zhang X, Li Q, Cong W, Mu S, Zhan R, Zhong S, et al. Effect of physical activity on risk of Alzheimer\u2019s disease: A systematic review and meta-analysis of twenty-nine prospective cohort studies. Ageing Res Rev. 2023;92:102127.","journal-title":"Ageing Res Rev"},{"key":"4188_CR131","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14390","volume":"21","author":"DM van Lent","year":"2025","unstructured":"van Lent DM, Mesa HG, Short MI, Gonzales MM, Aparicio HJ, Salinas J, et al. Association between dietary inflammatory index score and incident dementia. Alzheimers Dement J Alzheimers Assoc. 2025;21:e14390.","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"4188_CR132","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jalz.2010.11.002","volume":"7","author":"WA Rocca","year":"2011","unstructured":"Rocca WA, Petersen RC, Knopman DS, Hebert LE, Evans DA, Hall KS, et al. Trends in the incidence and prevalence of Alzheimer\u2019s disease, dementia, and cognitive impairment in the United States. Alzheimers Dement J Alzheimers Assoc. 2011;7:80\u201393.","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"4188_CR133","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1146\/annurev-neuro-080317-061725","volume":"41","author":"B Zott","year":"2018","unstructured":"Zott B, Busche MA, Sperling RA, Konnerth A. What happens with the circuit in Alzheimer\u2019s disease in mice and humans?. Annu Rev Neurosci. 2018;41:277\u201397.","journal-title":"Annu Rev Neurosci"},{"key":"4188_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101726","volume":"81","author":"P Piscopo","year":"2022","unstructured":"Piscopo P, Crestini A, Carbone E, Rivabene R, Ancidoni A, Lo Giudice M, et al. A systematic review on drugs for synaptic plasticity in the treatment of dementia. Ageing Res Rev. 2022;81:101726.","journal-title":"Ageing Res Rev"},{"key":"4188_CR135","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3390\/md19050251","volume":"19","author":"MT Kabir","year":"2021","unstructured":"Kabir MT, Uddin MS, Jeandet P, Emran TB, Mitra S, Albadrani GM, et al. Anti-Alzheimer\u2019s molecules derived from marine life: understanding molecular mechanisms and therapeutic potential. Mar Drugs. 2021;19:251.","journal-title":"Mar Drugs"},{"key":"4188_CR136","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s13346-011-0037-z","volume":"1","author":"CD Herzog","year":"2011","unstructured":"Herzog CD, Bishop KM, Brown L, Wilson A, Kordower JH, Bartus RT. Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically active neurotrophic factor proteins for neurodegenerative diseases. Drug Deliv Transl Res. 2011;1:361\u201382.","journal-title":"Drug Deliv Transl Res"},{"key":"4188_CR137","doi-asserted-by":"publisher","first-page":"r1148","DOI":"10.1136\/bmj.r1148","volume":"389","author":"E Mahase","year":"2025","unstructured":"Mahase E. Alzheimer\u2019s disease: Rise in new drugs being trialled sparks hope among experts. BMJ. 2025;389:r1148.","journal-title":"BMJ"},{"key":"4188_CR138","doi-asserted-by":"publisher","first-page":"5225","DOI":"10.1073\/pnas.1422998112","volume":"112","author":"S-S Jiao","year":"2015","unstructured":"Jiao S-S, Yao X-Q, Liu Y-H, Wang Q-H, Zeng F, Lu J-J, et al. Edaravone alleviates Alzheimer\u2019s disease-type pathologies and cognitive deficits. Proc Natl Acad Sci USA. 2015;112:5225\u201330.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4188_CR139","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41392-025-02145-7","volume":"10","author":"Q Jiang","year":"2025","unstructured":"Jiang Q, Liu J, Huang S, Wang X-Y, Chen X, Liu G-H, et al. Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances. Signal Transduct Target Ther. 2025;10:76.","journal-title":"Signal Transduct Target Ther"},{"key":"4188_CR140","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60903-1","volume":"16","author":"S Lv","year":"2025","unstructured":"Lv S, Mo F, Xu Z, Wang Y, Liu Y, Han M, et al. Integrated dopamine sensing and 40 Hz hippocampal stimulation improves cognitive performance in Alzheimer\u2019s mouse models. Nat Commun. 2025;16:5948.","journal-title":"Nat Commun"},{"key":"4188_CR141","doi-asserted-by":"publisher","DOI":"10.1126\/science.adu2987","volume":"388","author":"S Wang","year":"2025","unstructured":"Wang S, Jiang C, Yu Y, Zhang Z, Quhe R, Yang R, et al. Tellurium nanowire retinal nanoprosthesis improves vision in models of blindness. Science. 2025;388:eadu2987.","journal-title":"Science"},{"key":"4188_CR142","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.stem.2023.02.006","volume":"30","author":"Y-D Li","year":"2023","unstructured":"Li Y-D, Luo Y-J, Xie L, Tart DS, Sheehy RN, Zhang L, et al. Activation of hypothalamic-enhanced adult-born neurons restores cognitive and affective function in Alzheimer\u2019s disease. Cell Stem Cell. 2023;30:415\u2013432.e6.","journal-title":"Cell Stem Cell"},{"key":"4188_CR143","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3233\/JAD-160565","volume":"56","author":"M Boada","year":"2017","unstructured":"Boada M, Anaya F, Ortiz P, Olazar\u00e1n J, Shua-Haim JR, Obisesan TO, et al. Efficacy and safety of plasma exchange with 5% albumin to modify cerebrospinal fluid and plasma Amyloid-\u03b2 concentrations and cognition outcomes in Alzheimer\u2019s disease patients: a multicenter, randomized, controlled clinical trial. J Alzheimers Dis JAD. 2017;56:129\u201343.","journal-title":"J Alzheimers Dis JAD"},{"key":"4188_CR144","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/alz.12137","volume":"16","author":"M Boada","year":"2020","unstructured":"Boada M, L\u00f3pez OL, Olazar\u00e1n J, N\u00fa\u00f1ez L, Pfeffer M, Paricio M, et al. A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer\u2019s disease: Primary results of the AMBAR Study. Alzheimers Dement J Alzheimers Assoc. 2020;16:1412\u201325.","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"4188_CR145","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1038\/s41591-023-02543-w","volume":"29","author":"MM Gonzales","year":"2023","unstructured":"Gonzales MM, Garbarino VR, Kautz TF, Palavicini JP, Lopez-Cruzan M, Dehkordi SK, et al. Senolytic therapy in mild Alzheimer\u2019s disease: a phase 1 feasibility trial. Nat Med. 2023;29:2481\u20138.","journal-title":"Nat Med"},{"key":"4188_CR146","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.ebiom.2018.12.052","volume":"40","author":"JN Justice","year":"2019","unstructured":"Justice JN, Nambiar AM, Tchkonia T, LeBrasseur NK, Pascual R, Hashmi SK, et al. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine. 2019;40:554\u201363.","journal-title":"EBioMedicine"},{"key":"4188_CR147","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118627","volume":"264","author":"P Kesika","year":"2021","unstructured":"Kesika P, Suganthy N, Sivamaruthi BS, Chaiyasut C. Role of gut-brain axis, gut microbial composition, and probiotic intervention in Alzheimer\u2019s disease. Life Sci. 2021;264:118627.","journal-title":"Life Sci"},{"key":"4188_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2024.100016","volume":"12","author":"S Macfarlane","year":"2025","unstructured":"Macfarlane S, Grimmer T, Teo K, O\u2019Brien TJ, Woodward M, Grunfeld J, et al. Blarcamesine for the treatment of Early Alzheimer\u2019s Disease: Results from the ANAVEX2-73-AD-004 Phase IIB\/III trial. J Prev Alzheimers Dis. 2025;12:100016.","journal-title":"J Prev Alzheimers Dis"},{"key":"4188_CR149","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","volume":"380","author":"MF Egan","year":"2019","unstructured":"Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, et al. Randomized trial of verubecestat for prodromal Alzheimer\u2019s disease. N Engl J Med. 2019;380:1408\u201320.","journal-title":"N Engl J Med"},{"key":"4188_CR150","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1210951","volume":"369","author":"RS Doody","year":"2013","unstructured":"Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease. N Engl J Med. 2013;369:341\u201350.","journal-title":"N Engl J Med"},{"key":"4188_CR151","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nature09325","volume":"467","author":"G He","year":"2010","unstructured":"He G, Luo W, Li P, Remmers C, Netzer WJ, Hendrick J, et al. Gamma-secretase activating protein is a therapeutic target for Alzheimer\u2019s disease. Nature. 2010;467:95\u201398.","journal-title":"Nature"},{"key":"4188_CR152","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.biopsych.2020.02.001","volume":"89","author":"H Hampel","year":"2021","unstructured":"Hampel H, Vassar R, De Strooper B, Hardy J, Willem M, Singh N, et al. The \u03b2-Secretase BACE1 in Alzheimer\u2019s disease. Biol Psychiatry. 2021;89:745\u201356.","journal-title":"Biol Psychiatry"},{"key":"4188_CR153","doi-asserted-by":"publisher","DOI":"10.1126\/science.ads3972","volume":"391","author":"Y Chen","year":"2026","unstructured":"Chen Y, Liu Y, Nguyen K, Wu J, Song S, Lin K, et al. Targeting amyloid-\u03b2 pathology by chimeric antigen receptor astrocyte (CAR-A) therapy. Science. 2026;391:eads3972.","journal-title":"Science"},{"key":"4188_CR154","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.175015","volume":"9","author":"AB Kim","year":"2024","unstructured":"Kim AB, Xiao Q, Yan P, Pan Q, Pandey G, Grathwohl S, et al. Chimeric antigen receptor macrophages target and resorb amyloid plaques. JCI Insight. 2024;9:e175015.","journal-title":"JCI Insight"},{"key":"4188_CR155","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2530977123","volume":"123","author":"P Boskovic","year":"2026","unstructured":"Boskovic P, Shalita R, Gao W, Vernon H, Deng YL, Colonna M, et al. Engineering chimeric antigen receptor CD4 T cells for Alzheimer\u2019s disease. Proc Natl Acad Sci USA. 2026;123:e2530977123.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4188_CR156","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adl1123","volume":"10","author":"P-Y Sun","year":"2024","unstructured":"Sun P-Y, Liu J, Hu J-N, Tu Y-F, Jiang Q, Jia Y-J, et al. Rejuvenation of peripheral immune cells attenuates Alzheimer\u2019s disease-like pathologies and behavioral deficits in a mouse model. Sci Adv. 2024;10:eadl1123.","journal-title":"Sci Adv"},{"key":"4188_CR157","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370:322\u201333.","journal-title":"N Engl J Med"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04188-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04188-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04188-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:03:16Z","timestamp":1790820196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04188-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":157,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4188"],"URL":"https:\/\/doi.org\/10.1038\/s41398-026-04188-y","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"23 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"503"}}